Use of preoperative serum CA-125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer

Acta Obstetricia et Gynecologica Scandinavica

Volumn 85, Issue 12, 2006, Pages 1501-1505

  Hoon Chung, Hyun ^a   Weon Kim, Jae ^a   Park, Noh Hyun ^a   Song, Yong Sang ^a   Kang, Soon Beom ^a   Lee, Hyo Pyo ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

CA 125; Endometrial cancer; Lymph node; Prognosis

Indexed keywords

CA 125 ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASCITES FLUID CYTOLOGY; BLOOD LEVEL; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENDOMETRIUM CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LOGISTIC REGRESSION ANALYSIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; MYOMETRIUM; OUTCOME ASSESSMENT; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS;

CA-125 ANTIGEN; CARCINOMA, ENDOMETRIOID; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; LOGISTIC MODELS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 33845247785     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1080/00016340601022777     Document Type: Article

References (23)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
2. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer. 1987;60:2035-41.
3. Boronow RC, Morrow CP, Creasman WT, Disaia PJ, Silverberg SG, Miller A, et al. Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study. Obstet Gynecol. 1984;63:825-32.
4. Ayhan A, Tuncer R, Tuncer ZS, Yuce K, Kucukali T. Correlation between clinical and histopathologic risk factors and lymph node metastases in early endometrial cancer (a multivariate analysis of 183 cases). Int J Gynecol Cancer. 1994;4:306-9.
5. Fanning J, Piver MS. Serial CA 125 levels during chemotherapy for metastatic or recurrent endometrial cancer. Obstet Gynecol. 1991;77:278-80.
6. Niloff JM, Klug TL, Schaetzl E, Zurawski VR, Jr, Knapp RC, Bast RC, Jr. Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol. 1984;148:1057-8.
7. Duk JM, Aalders JG, Fleuren GJ, de Bruijn HW. CA 125: a useful marker in endometrial carcinoma. Am J Obstet Gynecol. 1986;155:1097-102.
8. Rose PG, Sommers RM, Reale FR, Hunter RE, Fournier L, Nelson BE. Serial serum CA 125 measurements for evaluation of recurrence in patients with endometrial carcinoma. Obstet Gynecol. 1994;84:12-6.
9. Patsner B, Mann WJ, Cohen H, Loesch M. Predictive value of preoperative serum CA 125 levels in clinically localized and advanced endometrial carcinoma. Am J Obstet Gynecol. 1988;158:399-402.
10. Scambia G, Gadducci A, Panici PB, Foti E, Ferdeghini M, Ferrandina G, et al. Combined use of CA 125 and CA 15-3 in patients with endometrial carcinoma. Gynecol Oncol. 1994;54:292-7.
11. Powell JL, Hill KA, Shiro BC, Diehl SJ, Gajewski WH. Preoperative serum CA12-5 levels in treating endometrial cancer. J Reprod Med. 2005;50:585-90.
12. Panici PB, Maggioni A, Hacker N, Landoni F, Ackermann S, Campagnutta E, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst. 2005;97:560-6.
13. DiSaia PJ, Creasman WT, Boronow RC, Blessing JA. Risk factors and recurrent patterns in Stage I endometrial cancer. Am J Obstet Gynecol. 1985;151:1009-15.
14. Soper JT, Berchuck A, Olt GJ, Soisson AP, Clarke-Pearson DL, Bast RC, Jr. Preoperative evaluation of serum CA 125, TAG 72, and CA 15-3 in patients with endometrial carcinoma. Am J Obstet Gynecol. 1990;163:1204-9.
15. Takeshima N, Shimizu Y, Umezawa S, Hirai Y, Chen JT, Fujimoto I, et al. Combined assay of serum levels of CA125 and CA19-9 in endometrial carcinoma. Gynecol Oncol. 1994;54:321-6.
16. Sood AK, Buller RE, Burger RA, Dawson JD, Sorosky JI, Berman M. Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome. Obstet Gynecol. 1997;90:441-7.
17. Yamazawa K, Hirashiki K, Usui H, Mitsuhashi A, Matsui H, Sekiya S. Discordance between serum level and tissue immunohistochemical staining of CA125 in endometrioid adenocarcinoma of the uterine corpus. Int J Gynecol Pathol. 2005;24:254-9.
18. National Statistical Office RoK. The Causes of Death Statistics (Death and Death rates). 2004.
19. Peters-Engl C, Buxbaum P, Ogris E, Sevelda P, Medl M. TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer. Anticancer Res. 1998;18:4635-9.
20. Koper NP, Massuger LF, Thomas CM, Kiemeney LA, Verbeek AL. Serum CA 125 measurements to identify patients with endometrial cancer who require lymphadenectomy. Anticancer Res. 1998;18:1897-902.
21. Frumovitz M, Singh DK, Meyer L, Smith DH, Wertheim I, Resnik E, et al. Predictors of final histology in patients with endometrial cancer. Gynecol Oncol. 2004;95:463-8.
22. Santala M, Talvensaari-Mattila A, Kauppila A. Peritoneal cytology and preoperative serum CA 125 level are important prognostic indicators of overall survival in advanced endometrial cancer. Anticancer Res. 2003;23:3097-103.
23. Alagoz T, Buller RE, Berman M, Anderson B, Manetta A, DiSaia P. What is a normal CA125 level? Gynecol Oncol. 1994;53:93-7.